Introduction
ONYX-015 is a type 2/5 chimeric adenovirus that has been genetically modified by attenuation of the E1B-55 kDa gene.
1 E1B-55 kDa, in complex with an E4ORF6 protein, binds to and inactivates the p53 tumor suppressor gene product. 2 Although the initial hypothesis was that ONYX-015 would replicate selectively in cells lacking p53 function, 3 subsequent work with different cell systems resulted in conflicting data linking the selectivity of ONYX-015 to p53 function, [4] [5] [6] [7] although most data are consistent with the role of p53 in modulating the replication of the virus. Several groups, in addition, have confirmed that the pathogenicity of ONYX-015 in normal cells is reduced as compared to wild-type adenovirus. 4, 8 Preclinical in vitro and in vivo combination studies demonstrated that combination of ONYX-015 with chemotherapeutic agents such as cisplatin or 5FU results in synergy. 8 In addition, development of resistance to cisplatin or doxorubicin can render cancer cells susceptible to ONYX-015 replication despite a wild-type p53 status. 9, 10 Its selectivity of replication against cancer cells, the favorable therapeutic index and its synergistic potential with commonly used chemotherapy agents rendered ONYX-015 a good candidate for clinical translation.
ONYX-015 has been tested in a variety of clinical settings and different routes of administration, including head and neck cancer (intratumoral administration), 11 pancreatic cancer (administration via endoscopic ultrasound), 12 metastatic colorectal cancer (administration via the hepatic artery) 13 or intravenously, 14 and ovarian cancer (intraperitoneal administration). 15 The most promising clinical results in these studies were obtained in the head and neck cancer study 11 and in the hepatic artery administration study: 13 in both trials, ONYX-015 was administered in combination with 5FU and/or cisplatin chemotherapy, pointing to the therapeutic potential of combining chemotherapy with virotherapy. Recurrent soft tissue sarcomas are malignancies refractory to chemotherapy. Response rates range from 15 to 30%. [16] [17] [18] Sarcomas represent a rational target for treatment with ONYX-015. They have a high frequency of p53 mutations ranging from 40 to 75%. In addition, MDM-2 gene amplification, which can result in functional p53 inactivation, occurs in another 10-30% of sarcoma cases. 19, 20 Furthermore, in preclinical experiments, ONYX-015 has been shown to replicate effectively and cause cytotoxicity 19 in the sarcoma line S4052. To further augment its antitumor activity, we combined ONYX-015 with antisarcoma agents that either are synergistic with ONYX-015, such as cisplatin, 8 or for which ONYX-015 can reverse resistance, such as doxorubicin. Therefore, we chose to combine ONYX-015 with the chemotherapy regimen MAP in this phase I/II study. MAP is a chemotherapy regimen, consisting of mitomycin-C, doxorubicin, and cisplatin 17 with known activity in advanced sarcomas. In a randomized prospective study, MAP demonstrated comparable activity to the ifosfamide/doxorubicin combination for most sarcoma histologies, but with significantly less myelosuppression. 21 Goals of this phase I/II trial were: (1) to define the maximum tolerated dose (MTD) of ONYX-015 in combination with MAP chemotherapy (mitomycin C, doxorubicin, and cisplatin) in patients with metastatic sarcoma, (2) to assess ONYX-015 replication in sarcomas, (3) to assess the antitumor activity of the regimen (secondary endpoint), (4) to correlate in a preliminary fashion ONYX-015 replication with the presence of neutralizing antibodies, and (5) to correlate any observed responses with the p53 and MDM-2 tumor status.
Our study demonstrated the safety, feasibility, and antitumor activity of this approach. Furthermore, our results provide for the first time evidence for in vivo replication of a conditionally replicating adenovirus in sarcoma tissue. Table 1 summarizes the baseline patient characteristics. A total of six patients were treated, two males and four female subjects. The median age was 53.5 years, ranging from 30 to 69 years. Two patients had leiomyosarcomas (both grade 3), two gastrointestinal stromal tumors (GIST), one liposarcoma (grade 2), and one malignant peripheral nerve sheath tumor (grade 3). Five out of six patients had not received prior chemotherapy for metastatic disease.
Results

Patient characteristics
Treatment characteristics
Six patients were treated, one per dose level at the lower dose levels (10 9 and 3 Â 10 9 plaque forming units (PFU)/ dose) and four at the highest dose level (10 10 PFU/dose). Study patients received from one to six treatment cycles. The median number of cycles was 2 and the mean number of cycles was 2.7. The location of the ONYX-015 injected lesion was liver in four out of six patients and chest wall masses in two out of six patients.
Toxicity
Figure 1 summarizes treatment-related toxicities depending on their attribution: possibly, probably or definitely related to ONYX-015; possibly, probably or definitely related to the MAP chemotherapy regimen; or possibly, probably or definitely related to both. Figure 2 similarly summarizes toxicity for cycles 2-6. Most of the treatment-related toxicity was due to MAP chemotherapy. Comparison of toxicity between cycle 1 and cycles 2-6 indicates there was no aggravation of toxicity observed with subsequent treatment cycles. ONYX-015 was very well tolerated with only toxicities attributed to virus alone being grade 1 fever or grades 1-2 pain at the injection site. The toxicities related to both ONYX-015 and MAP chemotherapy were also mild and consisted mainly of anorexia, fatigue, myalgia, and rigors. The grade 3 toxicities attributed to the combination included one incident each of diarrhea, nausea, vomiting in cycle 1 (all occurring in one patient) and two incidents of grade 3 anemia for cycles 2-6. No patient had to discontinue treatment because of toxicity. Table 2 summarizes the clinical responses. One patient with a metastatic malignant peripheral nerve sheath tumor achieved a partial response. The patient had ONYX-015 administered into a 7.3 Â 3.8 cm left paraspinal chest wall mass, which decreased in size by approximately 70%. Two other small uninjected lung nodules, measuring at baseline 2 Â 1.6 cm and 1 Â 1 cm, respectively, decreased in size by approximately 75 and 50%, while the remainder of her disease remained stable. The patient's partial response lasted for 11 months at which point regrowth of the injected lesion was observed. In addition, four patients had stable disease, Owing to the small number of patients, and the fact that all patients were p53 and/or mdm2 positive (Table 3) , and the fact that the majority of patients treated at the highest dose levels had evidence of viral replication by quantitative PCR and/or in situ hybridization, no association can be made between p53 status, mdm2 status and viral replication or response to treatment.
Clinical responses
Antiadenoviral immunity
Neutralizing antibodies were positive (41:20) at baseline in two out of four patients tested. Titers increased and/or became positive, in all tested patients after intratumoral administration of ONYX-015 with a median antibody titer after a single cycle of treatment of 1:3300.
Viral genome detection in the peripheral blood
Viral genomes were detected in the peripheral blood on day 5 (24 h after the fourth and prior to the fifth viral dose) in all patients at the two highest dose levels. One patient had additional sampling performed on days 8, 10, and 12 of cycle 1 (3, 5, and 7 days after the last viral administration). After a temporary drop on day 10 (Table 3) , viral copy number increased again in plasma on day 12 indicating ongoing viral replication.
Detection of viral DNA in tumor tissue by in situ hybridization
In situ hybridization demonstrated foci of viral DNA consisting of clusters of 5-20 positive nuclei in tumors of two out of four patients treated at the highest dose level (Figure 3 ), thus suggesting viral replication. There was no background staining and no positivity was observed in surrounding normal tissue.
Discussion
Sarcomas are connective tissue malignancies that, when relapsed, are frequently refractory to treatment. Therefore, there is an urgent need for developing of novel targeted therapeutics in this setting. Owing to their relative rarity, sarcomas are usually not included in clinical gene therapy/virotherapy efforts; the only other completed clinical gene transfer trial in the treatment of sarcomas was a phase I/II study of intratumoral Figure 1 Cycle 1 toxicity presented according to the attribution: total versus ONYX-015-related versus MAP-related versus ONYX-015/MAP combination-related. Most of treatment toxicity is due to MAP. Toxicities attributed to ONYX-015 or to the combination were generally mild and consisted of grades 1-2 constitutional symptoms and grade 1 injection site pain. One patient experienced grade 3 diarrhea, nausea, and vomiting, which were attributed to the combination treatment and were probably related to MAP chemotherapy.
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Sarcomas represent an excellent substrate for ONYX-015 because of the high frequency of p53 pathway malfunction: 40-75% of the patients have p53 mutations 19, 20 and an additional 10-30% have MDM-2 gene amplification. 19, 20 Our trial showed that ONYX-015, both as a single agent and in combination with MAP chemotherapy, was well tolerated. This is consistent with a favorable safety profile of ONYX-015 alone and in combination with cytotoxic chemotherapy including agents such as 5FU and/or CDDP after intratumoral, 11 intra-arterial, 13 and intravenous administration of the virus 23 in other tumor types. Administration of ONYX-015 was very well tolerated despite the fact that five injections per treatment cycle were performed in deepseated lesions: patients have had up to a total of 30 injections (six treatment cycles), with practically no injection-related complications except for one patient experiencing grade 2 injection site pain during treatment of a large recurrent chest wall liposarcoma. Of note, coadministration of ONYX-015 with chemotherapy in our trial did not aggravate either toxicities due to ONYX-015 or toxicities due to chemotherapy. This observation is consistent with prior combination studies, 11, 13 thus emphasizing that combination of replicating adenoviruses with chemotherapy is feasible, and generally well tolerated. Given preclinical 9 and clinical data 11 indicating synergy and possible enhancement of antitumor efficacy, combinations of replicating viruses with chemotherapy regimens represent a direction worth investigating further. Our data provide evidence supporting ONYX-015 replication in sarcoma lesions in vivo. ONYX-015 was detected by quantitative PCR 24 h after the fourth intratumoral injection in the peripheral blood of all five patients treated in the two highest dose levels. One patient in addition had repeat sampling ONYX-015 in combination with MAP chemotherapy in sarcomas E Galanis et al performed on days 8, 10, and 12 (i.e., 3, 5, and 7 days after the last viral administration): a second peak in the genome number was observed on day 12 after a temporary drop on day 10, consistent with viral replication. In addition, ONYX-015 DNA was detected by in situ hybridization on day 5 in sarcoma biopsies from two patients treated at the highest dose level. ONYX
In situ hybridization positivity in our patients was focal, usually observed in clusters of 5-20 cells. Although this could be interpreted as limited viral replication in vivo, other contributing factors include sampling effect and small number of tumor cells in biopsy specimens and emphasize the difficulties associated with use of needle biopsies to assess viral replication in vivo.
In situ hybridization and detection of adenoviral genomes in the peripheral blood by quantitative PCR are complementary methods in assessing ONYX-015 replication. Although assessment of replication by in situ hybridization is appealing since it allows assessment of the nature and distribution of the infected cells, it is limited by sampling variations and the small amount of tissue assessed, which can lead to false negative results. Ethical and practical considerations also limit the number of samples that can be obtained per patient. In contrast, quantitative PCR is more practical since multiple blood samples per patient can be obtained and more time points can be examined. It can be limited, however, by the fact that viral shedding in the bloodstream is required for detection. These limitations are also applicable to other replicating vectors and emphasize the need for development of methodology that would allow realtime monitoring of viral replication in the context of clinical trials. One possible solution to this problem is incorporation of soluble marker peptide genes in the genome of the therapeutic virus. Subsequently, detection of the peptide in the serum can serve as a correlate of viral gene expression. [24] [25] [26] The first clinical trial testing this concept is currently ongoing. 27 Different tumor types can vary significantly in their permissiveness for viral infection and replication. In addition to sarcomas, other tumor types permissive to adenoviral infection in the clinical setting include head and neck cancer, where 70% of patients had evidence of viral replication 1-3 days from last treatment 28 by either biopsy analysis or PCR of the peripheral blood. In addition, ONYX-015 replication has been demonstrated in colorectal tumors after either hepatic artery administration 13 where five out of seven patients had viremia on days 4-5, following initial clearance of the virus, or after systemic administration 14 with 36% of patients having detectable genome levels at 72 h after intravenous (i.v.) administration of the virus. In contrast, patients with injected pancreatic tumors showed no evidence of viral replication by PCR or in situ hybridization. 12, 29 Similarly, no viral replication could be demonstrated by PCR after intraperitoneal administration of ONYX-015 in patients with recurrent ovarian cancer and only one out of 12 peritoneal fluid samples were weakly positive by in situ hybridization. 15 In our trial, one of four patients, treated at the highest dose level, achieved a partial response that lasted 11 months. Although in this patient the most significant regression was observed in the bulky ONYX-015 injected lesion, two small uninjected lesions also decreased in size, therefore, no definite conclusions regarding the impact of ONYX-015 on the observed antitumor effect can be made.
In summary, our phase I/II trial demonstrated that ONYX-015 in combination with a doxorubicin/cisplatin containing chemotherapy regimen appears to be well tolerated and has antitumor efficacy against sarcomas. There are several directions, where such a combination may prove to be beneficial, for example, in patients for whom local recurrence is the predominant presentation, after failure of other local modalities such as surgery or radiation therapy. Furthermore, ONYX-015 has been safely administered through the i.v. route. 14, 22 A phase I trial in cancer patients with lung metastases confirmed intratumoral replication of the virus in lung metastases, 22 therefore, indicating that the first passage of the virus through the lungs after i.v. administration can be exploited to target viral delivery. Sarcomas represent good candidates for such an approach since lungs are one of the most frequent locations for sarcoma metastasis. Tumor-specific promoters, such as the osteosarcoma-specific osteocalcin promotor, 30 could be employed to further enhance specificity.
Furthermore, our study provides evidence that ONYX-015 can replicate in sarcomas after intratumoral administration and can be safely administered in combination with standard sarcoma chemotherapy. Although a secondary end point in this study, antitumor efficacy was observed in a patient with a malignant peripheral nerve sheath tumor. Additional work to exploit this approach in patients with recurrent sarcoma is warranted.
Materials and methods
Inclusion/exclusion criteria
Patients were required to have histologic diagnosis of sarcoma beyond surgical cure with at least two measurable sites of metastatic disease, in one of which the injections of the viral agent were administered, while the other served as a control. The injected lesion should have been between 1 and 10 cm in size. Patients were 18 years of age or older, had life expectancy X3 months, and should have had adequate hematologic, renal, and hepatic function. Patients were excluded if they had any of the following: poor performance score of ECOG 3 or 4; uncontrolled infection; metastatic disease not amenable to intratumoral administration of the virus; other concurrent chemotherapy, immunotherapy or radiation therapy. Patients were allowed to have up to two prior regimens for metastatic disease. In order to avoid cardiotoxicity, patients with prior maximum dose of doxorubicin X250 mg/m 2 were not eligible. The protocol was approved by the Mayo Clinic Institutional Review Board and informed consent was obtained from all the patients.
Pretreatment evaluation/follow-up studies
Pretreatment evaluation included a history and physical examination, complete blood cell count, serum chemistries, and coagulation profile. Evaluation/measurement of injected and control tumors and assessment of disease status was performed by using appropriate imaging modalities such as CT scan, MRI, or chest X-ray. Followup studies included physical examination, complete blood cell counts, serum chemistries, and imaging performed every 4 weeks. Neutralizing antibody titers were obtained at baseline and prior to cycle 2. ONYX-015 genomes in the peripheral blood were quantified at baseline, on day 5 of cycle 1, and prior to cycle 2. In addition, one patient had extended sampling performed for viral kinetics, consisting of additional blood samples ONYX-015 in combination with MAP chemotherapy in sarcomas E Galanis et al on days 8, 10, and 12 (3, 5, and 7 days after the day 5 dose) of cycle 1. Tumor biopsy for confirmation of diagnosis and determination of p53 and mdm2 status was performed at baseline and repeat biopsy to assess viral replication by in situ hybridization (ISH) was obtained on day 5 of cycle 1.
Study drug
ONYX-015 is a chimeric human group C adenovirus, containing a deletion between nucleotides 2496 and 3323 in the E1B region encoding the 55 kDa protein.
Furthermore, a C to T transition at position 2022 in E1B results in a stop codon at the third codon position of the protein.
These changes eliminate expression of the E1B-55 kDa gene in ONYX-015-infected cells. The virus was produced in human embryonic kidney 293 cells, as previously described, 9 formulated in TRIS buffer (10 mM TRIS pH 7.4, 1 mM MgCl 2 , 150 mM NaCl, 10% glycerol) and supplied frozen (À201C) in 0.5 ml vials. The viral particle (vp) to PFU ratio was 20. Wild type adenovirus was undetectable in all clinical lots of ONYX-015 at a limit of detection of 1 in 10 11 particles. Thawed ONYX-015 was maintained at 2-81C during dilution and handling and administered to patients within 2 h from viral preparation.
Treatment schedule
The following three viral dose levels were employed; Level 1: 
Statistical methodology
The study employed a type 2 accelerated titration design as described by Simon et al. 31 This is a modification of the standard cohort of three design that was developed recently in order to reduce the number of patients treated at potentially suboptimal dose levels. One patient is entered at each dose level until toxicity of at least grade 2 is encountered, at which point the study is converted to a standard cohort of three design with three patients treated per dose level.
MTD was defined as the highest safely tolerated dose where p1 patient experiences dose-limiting toxicity (DLT) with the next higher dose level having at least two patients who experience DLT.
DLT was defined as follows: (a) hematologic toxicity: neutrophil count o500 for X5 days, hemoglobin o6.5 g/dl, or platelet count o25 000; (b) renal toxicity: serum creatinine X2 times the baseline; (c) all other nonhematologic toxicity: Xgrade 3 as per NCI Common Toxicity Criteria Version 2.0.
Toxicity and response criteria
Toxicity was graded on a scale of 0-4, using the National Cancer Institute on Common Toxicity Criteria Version 2.0.
Response was evaluated by the appropriate imaging modality CT, MRI, or chest X-ray prior to each treatment cycle. At least two measurable lesions were required according to our inclusion criteria; however, in addition, patients could have other measurable or evaluable sites of disease. Complete response was defined as complete disappearance of all evidence of tumor, maintained for at least 4 weeks. A partial response was defined as a decrease of X50% in the sum of the product of the perpendicular diameters of all measurable lesions maintained for at least 4 weeks with no new lesions, and no progression of evaluable disease. Progression of disease was defined as an increase of X25% in the sum of the products of the perpendicular diameters of all measurable lesions, appearance of new lesions or worsening of other evaluable disease. Patients with stable disease were defined as those not meeting the criteria for complete response, partial response, or progression of disease.
Immunohistochemistry for p53 and mdm2 expression
Immunohistochemistry of pretreatment biopsies was performed using an anti-p53 antibody from DAKO Cytomation (catalog #M7146, 1/200 dilution), an antimdm2 antibody from DAKO Cytomation (clone SMP14, 1/100 dilution), and the HRP+/DAB+ Chromagen substrate (DAKO Cytomation). Results of the stains were reported as positive or negative and positivity was quantified as follows: 1+ when o 10% of neoplastic cells were positive, 2+, when 10-50% of the neoplastic cells were positive and 3+, when 4 50% of the neoplastic cells were positive.
Plasma neutralizing antibody titers
Neutralizing antibodies directed against adenovirus type 5/ONYX-015 were determined using a cell-based plaque assay. Clinical plasma samples previously determined to produce high, midrange and negative titers were designated as plasma controls. Patient and control plasma samples were incubated at 551C for 30 min to inactivate complement and serially diluted. Each plasma dilution was mixed with ONYX-015 stock at a titer prequalified to produce 15-20 plaques per well in a 12-well dish format. The patient's samples and controls were inoculated for 1 h at room temperature, and then applied to 70-80% confluent HEK293 cells in 12-well dishes. After 2 h of incubation at 371C, the plasma-virus mix was replaced with 2 ml of 1.5% Agarose. Plates were read on day 7 postinoculation by counting the number of plaques per well. The titer of neutralizing antibody for each sample was reported as the dilution of plasma that reduced the number of plaques to 60% of the number of plaques in the virus control without patient plasma. The titer range of the neutralizing antibody titer assay is 1:20-1:81 920.
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Detection of ONYX-015 viral genome in plasma
A TaqMan-based PCR assay was developed to quantitate the amount of ONYX-015 virus in human plasma. Samples were tested independently by Althea Technologies (San Diego, CA, USA). The assay detects a 92 nt sequence from nt.2452-nt.2544. The amplicon overlaps the E1B region deletion and includes an 8 bp Puc-derived linker insert. The central region of the TaqMan probe is homologous to the linker insert, making the probe specific to ONYX-015, therefore, avoiding the spurious detection of wild-type adenovirus sequences.
Total DNA was extracted from plasma by adding 3 mg of carrier DNA to 500 ml of plasma and isolating total DNA using the QiaAmp Blood Kit (Qiagen, Almada, CA, USA). PCR amplification was performed using the following primers and probe: forward primer 5 0 GCTG GCGCAGAAGTATTCCA, reverse primer 5 0 GTGCGGG TCTCATCGTACCT and the probe 5 0FAM -ACCTTCCA GATCCGTCGACCTGCA-TAMRA . DNA was amplified using 10 mmol/l of each primer and the probe with the following cycling conditions: 2 min at 501C, 10 min at 951C, 40 cycles of 15 s at 951C (denaturation) and 40 cycles of 1 min at 631C (extension/annealing) in an ABI7700 DNA sequencer (Perkin-Elmer, ABI, Foster City, CA, USA). Two PCR reactions were performed for each sample using the same oligonucleotide primers and fluorescent probe, reaction conditions, and cycling conditions. To check for the presence of PCR inhibitors, an additional reaction was amplified using primers and probe specific for the 18s rRNA gene. Each PCR run contained one set of standards, extraction controls corresponding to the test articles on the plate, and a PCR reagent control, run in duplicate reactions. The limit of detection for the assay was 500 particles/ml as determined by using a control virus quantified by electron microscopy. The limit of quantification was 2000 particles/ml.
Detection of adenovirus DNA in tumor biopsies
ISH for adenovirus DNA was carried out on biopsy samples to determine the extent of replication of ONYX-015 in both tumor and adjacent normal tissue. Samples were formalin-fixed, paraffin-embedded and cut. Slides were deparaffinized in xylene, hydrated with ethanol, digested with proteinase K and fixed in 4% paraformaldehyde. Samples were hybridized overnight at 371C with 0.5 mg/ml biotinylated adenovirus DNA probe (Enzo Diagnostics, Farmingdale, NY, USA). Slides were then sequentially washed in 0.5 Â SSC and probe detection was carried out by using a streptavidin-alkaline phosphatase conjugate. Slides were stained with nitroblue tetrazolium/bromochloroindolyl phosphate (NBT/ BCIP) and counterstained with nuclear fast red. Three sections were stained per biopsy. Pathology interpretation including the subcellular localization of the staining was obtained on all biopsy samples.
